<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00157768</url>
  </required_header>
  <id_info>
    <org_study_id>Medtronic_BRC_CRM_002</org_study_id>
    <nct_id>NCT00157768</nct_id>
  </id_info>
  <brief_title>IRIS : Use of Implantable Defibrillator in High-risk Patients Early After Acute Myocardial Infarction</brief_title>
  <official_title>IRIS - Immediate Risk-stratification Improves Survival - Joint Study of the German University Hospitals and German Society of Leading Cardiological Hospital Physicians (ALKK)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <brief_summary>
    <textblock>
      Of the patients who survive hospitalization after an acute myocardial infarction, ca. 10% die&#xD;
      of sudden cardiac death in the following 2 years. The prognosis appears not improved by&#xD;
      medication with antiarrhythmics (class I/III). A positive effect of beta-blockers (Metoprolol&#xD;
      CR/Zok) on total mortality after myocardial infarction in patients with heart failure is well&#xD;
      established. On the other hand, an implantable defibrillator (ICD) proved to be superior to&#xD;
      medication when used for secondary prevention in patients after cardiac arrest. The question&#xD;
      arises whether ICD therapy is also effective in primary prevention in high risk patients&#xD;
      after acute myocardial infarction. This study determines if patients, who were defined as&#xD;
      high risk patients in the early post infarction phase by means of noninvasive methods,&#xD;
      benefit from primary prevention by means of an ICD. Special emphasis is put on an individual&#xD;
      optimization of the infarction therapy, including beta-blockers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 9, 1999</start_date>
  <completion_date type="Actual">October 15, 2007</completion_date>
  <primary_completion_date type="Actual">October 15, 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The null hypothesis is that all cause mortality in the treatment (Implantable cardioverter defibrillator =ICD) and control group is identical. The alternative hypothesis is that all cause mortality in the ICD group and control group is different.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type of death, Arrhythmic events, Serious cardiac and cerebral interventions,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device-related complications, Hospitalizations, Quality of life</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable cardioverter defibrillator</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  acute myocardial infarction (5-31 days)&#xD;
&#xD;
          -  fulfill requirement I and/or II :&#xD;
&#xD;
               -  I first ECG heart rate &gt;= 90 bpm (within day 1-2 post MI) and LVEF &lt;= 40 %&#xD;
                  (within day 5-31 post-MI)&#xD;
&#xD;
               -  II &gt;= 1 episode of non-sustained ventricular tachycardia &gt;= 150 bpm (on Holter,&#xD;
                  within 5-31 days post-MI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with ventricular arrhythmia, requiring clinical therapy, before the index&#xD;
             infarction or more than 48 h later&#xD;
&#xD;
          -  Patients with therapy refractory heart failure (NYHA IV)&#xD;
&#xD;
          -  Myocardial infarction older than 31 days&#xD;
&#xD;
          -  First-ECG not available or was recorded more than 48 h after the symptom onset.&#xD;
&#xD;
          -  Patients with indication for CABG operation before inclusion&#xD;
&#xD;
          -  Patients with cerebral organic psycho syndrome&#xD;
&#xD;
          -  Secondary diseases which clearly limit life expectancy&#xD;
&#xD;
          -  Patient with right sided artificial heart valve&#xD;
&#xD;
          -  Patients with poor compliance&#xD;
&#xD;
          -  Patients who are participating in another study&#xD;
&#xD;
          -  Unstable clinical condition&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  No consent from patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D. Andresen, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum am Urban, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. Senges, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Ludwigshafen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G. Steinbeck, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Grosshadern, Munich, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medtronic Bakken Research Center B.V.</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>October 5, 2018</last_update_submitted>
  <last_update_submitted_qc>October 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2018</last_update_posted>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Non-sustained ventricular tachycardia</keyword>
  <keyword>Left ventricular dysfunction</keyword>
  <keyword>Implantable cardioverter defibrillator</keyword>
  <keyword>ICD</keyword>
  <keyword>Risk-stratification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

